uniQure N.V. QURE 深 滬
等待開盤 02-04 09:30:00 美东时间
27.80
+3.100
+12.55%
華盛通- 最 高28.48
- 今 開25.10
- 成交量 468.33万股
- 最 低 24.82
- 昨 收 24.70
- 總市值 16.86亿
- 52周最高 71.50
- 市盈率 靜 --
- 換手率 0.01%
- 52周最低 7.76
- 委 比 -99.76%
- 總股本 6065.64万
- 歷史最高 82.49
- 量 比 3.06
- 振 幅 14.82%
- 歷史最低 3.73
- 每 手 1
- 風險率 14.61%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 希捷科技、德州仪器、HCA控股、通用汽车、波音、UPS等或多家机构上调目标价；布朗保险、康沃系统、Qorvo、联合健康等遭多家机构下调目标价
今日重点评级关注：Piper Sandler：维持Praxis Precision Medicine"超配"评级，目标价从450美元升至1200美元；Tigress Financial：维持Main International ETF"买入"评级，目标价从52美元升至66美元
01-29 11:06
Barclays Initiates Coverage On uniQure with Equal-Weight Rating, Announces Price Target of $31
Barclays analyst Eliana Merle initiates coverage on uniQure (NASDAQ:QURE) with a Equal-Weight rating and announces Price Target of $31.
01-28 22:55
uniQure Announces Type A Meeting Scheduled with FDA
uniQure N.V. has scheduled a Type A meeting with the U.S. FDA to discuss the BLA data package for AMT-130, its gene therapy for Huntington’s disease, aiming for accelerated approval. CEO Matt Kapusta expressed commitment to timely access for patients and collaboration with the FDA. The公司 plans to provide a regulatory update post-meeting and is advancing a pipeline of gene therapies for severe diseases.
01-09 12:05
Toro, DBV Technologies, Udemy, ABM Industries And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Dow Jones index gaining more than 150 points o...
2025-12-17 23:07
What's Going On With uniQure Stock On Tuesday?
uniQure shares slid nearly 31% in a month as the FDA raised concerns over whether AMT-130 Phase 1/2 data can support approval.
2025-12-17 01:17
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares moved upwards by 38.7% to...
2025-12-16 20:05
Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket
Shares of B Riley Financial Inc (NASDAQ:RILY) rose sharply in pre-market tradin...
2025-12-16 18:53
美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
2025-12-12 10:24
美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
2025-12-10 10:33
